Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Addex Therapeutics Ltd

Company price
3.47 USD 0.07 ( 2.06%)
Last update at 2026-11-20T21:00:00Z
VOLUME
18130
Market Cap
8.66M

Momentum Score

…

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.24
Low
3.53
High
52 Week Price Range
5.41
Low
12.05
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Addex Therapeutics is a clinical-stage biopharmaceutical company developing allosteric modulators of metabotropic glutamate receptors for central nervous system disorders. Its long-term growth drivers include clinical advancement of differentiated mGluR candidates, potential licensing or partnerships, and unmet needs in neurodegenerative and psychiatric diseases. Investors may find the company attractive for its novel mechanism that could offer selective targeting and for value creation tied to clinical milestones.
Major risks include clinical trial failure and regulatory setbacks, frequent need for external financing leading to dilution, and limited commercial track record and market liquidity.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.40
Dividend Yield
-
Revenue TTM
0.16M
Revenue Per Share
0.24
Gross Profit TTM
-0.53M
Debt / Equity
0.00
ROE
-72.84%
Net Debt
-3.30M
ROCE
-49.67%
Diluted EPS TTM
-9.18

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -4.91M -2.50M -20.80M -15.35M -12.86M
Net income 7.06M -10.56M -21.07M -15.41M -12.93M
Selling general administrative 1.68M 2.03M 7.30M 5.14M 5.15M
Selling and marketing expenses - 2.21M - - -
Gross profit 0.40M 1.61M 1.42M 2.92M 3.61M
Reconciled depreciation 0.26M 0.31M 0.32M 0.35M 0.38M
Ebit -4.91M -2.50M -20.52M -15.51M -12.24M
Ebitda -4.65M -2.19M -20.17M -15.15M -11.83M
Depreciation and amortization 0.26M 0.31M 0.35M 0.35M 0.41M
Operating income -2.76M -2.24M -20.52M -15.51M -12.24M
Other operating expenses 3.16M 3.86M 21.94M 18.42M 15.86M
Interest expense 0.00M 0.02M 0.05M 0.06M 0.07M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.01M 0.06M 0.03M 0.01M 0.04M
Net interest income 0.01M 0.04M -0.02M -0.06M -0.03M
Income tax expense - 0.02M 0.26M 0.06M 0.07M
Total revenue 0.40M 1.61M 1.42M 2.92M 3.61M
Total operating expenses 3.16M 3.86M 21.94M 18.42M 15.86M
Cost of revenue 0.85M 6.94M - - -
Total other income expense net -2.15M -0.26M -0.28M 0.15M -0.62M
Net income from continuing ops -4.91M -10.56M -20.80M -15.35M -12.86M
Net income applicable to common shares - - -20.80M -15.35M -12.86M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 10.68M 4.64M 8.28M 22.54M 20.18M
Other current assets 0.18M 0.22M 871.88M 1.12M 0.66M
Total liab 1.00M 3.50M 3.37M 5.61M 5.57M
Total stockholder equity 9.68M 1.15M 4.91M 16.93M 14.61M
Other current liab 0.52M 1.40M 1.72M 2.06M 1.51M
Common stock 1.84M 1.84M 1.15M 49.27M 32.85M
Capital stock 1.84M 1.84M 1.15M 49.27M 32.85M
Retained earnings -353.36M -360.42M -349.86M -329.06M -313.71M
Other liab - - - 1.28M 1.69M
Other assets - - 0.05M 0.06M 0.06M
Cash 3.34M 3.87M 6.96M 20.48M 18.70M
Total current liabilities 0.80M 2.89M 3.28M 4.13M 3.62M
Current deferred revenue - 0.23M - - 0.82M
Net debt -3.30M -3.52M -6.58M -20.00M -18.13M
Short term debt 0.01M 0.27M 0.29M 0.29M 0.31M
Short long term debt total 0.04M 0.34M 0.37M 0.48M 0.57M
Other stockholder equity 330.13M 329.91M 327.85M 272.28M 286.89M
Property plant equipment - - 0.40M 0.54M 0.63M
Total current assets 3.54M 4.23M 7.83M 21.94M 19.49M
Long term investments 7.09M - - - -
Net tangible assets - - 4.91M 16.93M 14.61M
Short term investments 0.01M 0.00M 0.00M 0.02M 0.06M
Net receivables 0.02M 0.15M 0.60M 0.32M 0.07M
Inventory - - -871.60M - -
Accounts payable 0.25M 0.98M 1.28M 1.79M 0.98M
Accumulated other comprehensive income 31.06M 29.81M 25.77M 24.44M 8.58M
Common stock total equity - - - - 32.85M
Non currrent assets other 0.01M 0.05M 0.05M 0.06M 0.06M
Non current assets total 7.14M 0.41M 0.45M 0.60M 0.69M
Capital lease obligations 0.04M 0.34M 0.37M 0.48M 0.57M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 4.65M -0.01M 0.00M 0.00M -0.06M
Change to liabilities - - -0.43M 0.06M -2.04M
Total cashflows from investing activities 4.65M -0.01M 0.00M -0.03M -0.06M
Net borrowings -0.07M -0.28M -0.29M -0.31M -0.37M
Total cash from financing activities 0.10M 5.26M 3.10M 16.40M 0.05M
Change to operating activities - - 0.86M -0.57M 0.17M
Net income 7.06M -10.56M -20.80M -15.35M -12.86M
Change in cash -0.52M -3.09M -13.53M 1.79M -12.84M
Begin period cash flow 3.87M 6.96M 20.48M 18.70M 31.54M
End period cash flow 3.34M 3.87M 6.96M 20.48M 18.70M
Total cash from operating activities -5.37M -7.99M -16.44M -14.71M -12.18M
Issuance of capital stock 0.24M 2.35M 1.68M 13.96M 0.72M
Depreciation 0.26M 0.31M 0.32M 0.35M 0.38M
Other cashflows from investing activities 5.12M - - - -
Dividends paid 0.00M 0.00M 0.00M 0.00M 0.00M
Change to inventory - 0.61M - - -
Change to account receivables 0.13M 0.31M -0.25M -0.10M 0.05M
Sale purchase of stock -0.00M -0.05M - - -
Other cashflows from financing activities -0.06M 3.20M 1.71M 2.75M -0.31M
Change to netincome - - 3.89M 1.06M 2.12M
Capital expenditures 0.00M 0.01M 0.00M 0.03M 0.06M
Change in working capital -1.23M 0.21M 0.16M -0.76M -1.82M
Stock based compensation - 1.79M 3.68M 1.18M 1.18M
Other non cash items -11.46M 0.25M 0.20M 0.03M 0.97M
Free cash flow -5.37M -8.00M -16.44M -14.74M -12.24M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ADXN
Addex Therapeutics Ltd
0.07
2.06%
3.47 - - 54.63 1.12 136.36 -0.76
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Addex Therapeutics Ltd

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Chemin des Mines, 9, Geneva, Switzerland, 1202

41 22 884 1555

2

Name Title Year Born
Mr. Timothy Mark Dyer Co-Founder, CEO & Director 1968
Dr. Roger G. Mills M.D. Chief Medical Officer & Director 1957
Mr. Lénaic Teyssédou Head of Fin. 1986
Dr. Jean-Philippe Rocher Ph.D. Head of Discovery - Chemistry 1959
Dr. Robert Lutjens Head of Discovery - Biology 1968
Dr. Mikhail Kalinichev Ph.D. Head of Translational Science 1968
Dr. Werner Henrichi Ph.D. Consultant 1943
Mr. Lénaic Teyssédou Head of Finance 1986
Dr. Mikhail Kalinichev Ph.D. Head of Translational Science 1967

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…